Last updated: June 3, 2026
Most peptides are degraded in the GI tract before reaching circulation, which is why subcutaneous injection is the standard route. Oral bioavailability for unmodified peptides is typically <1%. Successful oral peptide drugs use absorption enhancers (Rybelsus uses SNAC), special formulations (BPC-157 is naturally gastric-stable), or smaller modifications. Intranasal delivery (Selank, Semax) bypasses GI degradation while avoiding injection.
[/gtp_tldr]
Why oral peptide delivery is hard
Three barriers prevent oral peptide absorption:
- Stomach acid (pH 1-3): Hydrolyzes peptide bonds
- Digestive enzymes: Pepsin, trypsin, chymotrypsin cleave peptides into amino acids
- Intestinal mucus barrier: Limits absorption of large molecules
The net result: <1% of an unmodified orally-administered peptide reaches systemic circulation.
Routes of administration ranked by bioavailability
| Route | Typical bioavailability |
|---|---|
| Subcutaneous injection | ~60-100% |
| Intramuscular injection | ~60-100% |
| Intranasal | ~5-30% (varies widely) |
| Sublingual | ~5-20% |
| Oral with absorption enhancer | ~1-5% |
| Oral unmodified | <1% |
Successful oral peptide drugs
Rybelsus (oral semaglutide)
Uses SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) absorption enhancer. SNAC raises gastric pH locally and increases membrane permeability. Bioavailability ~1% — still requires much higher dose than injection. 14 mg oral ≈ 0.5 mg injected.
Cyclosporine
Cyclic peptide that resists enzymatic degradation. Oral bioavailability ~30%.
BPC-157
Reported gastric-stable, derived from a sequence in gastric juice. Animal studies suggest oral activity.
Intranasal peptides
Intranasal delivery bypasses GI degradation while avoiding injection. Used clinically for:
- Oxytocin (research applications)
- Calcitonin (Miacalcin nasal spray)
- Selank, Semax (Russian-approved)
- Insulin (research products)
- Desmopressin (FDA-approved for diabetes insipidus)
Why we still inject most peptides
Subcutaneous injection remains the gold standard because:
- Reliable, predictable bioavailability
- No first-pass metabolism issues
- Allows lower doses than oral (avoiding cost issues)
- Reaches systemic circulation directly
Are oral peptides as effective as injectable?<br />
Generally no. Oral semaglutide (Rybelsus) at 14 mg approximates 0.5 mg injected — significantly less effective per labeled mg.
Will more oral peptides be approved?<br />
Yes. Multiple oral GLP-1 candidates in late-stage trials (orforglipron is non-peptide, but danuglipron and others). Oral PYY analogs and oral PTH analogs in development.
Is sublingual delivery effective?<br />
Variable. Sublingual bioavailability for peptides is typically 5-20% — better than oral but still much less than injection.
Why are some peptides given by nasal spray?<br />
Intranasal delivery bypasses GI degradation and avoids needles, but bioavailability is still variable (5-30%) and inconsistent.
Related guides: How to measure peptide doses · Peptide side effects · Are peptides safe?